Deutsche Bank Would Buy Gilead Sciences (GILD) on Weakness
GILD Hot Sheet
Rating Summary:12 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 9 | New: 35
Deutsche Bank said they would buy Gilead Sciences (NASDAQ: GILD) on this morning's weakness related to disappointing GS-7977 data.
The firm said the fair value of GILD under "disasters" scenarios is: 1. Only in GT2-6 No GT1: GILD $40-$44 - "This assumes the Base Biz $35.5-39 + $5 Hep-C. Range in HIV base biz assumes 20-35% new patient share for QUAD." 2. Low 15% overall share with 7977 in Gt1: GILD $48-$52 - "60% share in GT2-6 (assuming ~30% GT-1 are treatmetn naives): (Base biz $35.5- 39 + $13 Hep-C)."
However, Deutsche Bank said a "disasters" scenario is not likely, citing:
(1) THIS IS NULL DATA- Navies are likely to look better. Likely GILD can take
more than 15% market share.
(2) GILD has an arsenal of OTHER DAAs they can combine to get a combo
that can take 60% share. They likely can move that into clinic this summer
in phase 2..and still be on track for phase 3 early 2013.
(3) ALL THESE ASSUME LOW HIV- there is still potentially $10/share of
UPSDIE IN HIV in 2012 is possible.
The firm maintained their Buy rating and price target of $66 on GILD.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences are down 19% to $44.11.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
The firm said the fair value of GILD under "disasters" scenarios is: 1. Only in GT2-6 No GT1: GILD $40-$44 - "This assumes the Base Biz $35.5-39 + $5 Hep-C. Range in HIV base biz assumes 20-35% new patient share for QUAD." 2. Low 15% overall share with 7977 in Gt1: GILD $48-$52 - "60% share in GT2-6 (assuming ~30% GT-1 are treatmetn naives): (Base biz $35.5- 39 + $13 Hep-C)."
However, Deutsche Bank said a "disasters" scenario is not likely, citing:
(1) THIS IS NULL DATA- Navies are likely to look better. Likely GILD can take
more than 15% market share.
(2) GILD has an arsenal of OTHER DAAs they can combine to get a combo
that can take 60% share. They likely can move that into clinic this summer
in phase 2..and still be on track for phase 3 early 2013.
(3) ALL THESE ASSUME LOW HIV- there is still potentially $10/share of
UPSDIE IN HIV in 2012 is possible.
The firm maintained their Buy rating and price target of $66 on GILD.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences are down 19% to $44.11.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Morgan Stanley (MS) Treated Facebook (FB) IPO Like Other Offerings, Said Revised S-1 Was Widely Publicized
- Compass Point Maintains a 'Neutral' on UDR, Inc. (UDR); Raising PT, But Lowering Estimates
- Brean Murray Carret & Co. Reiterates a 'Sell' on Urban Outfitters (URBN); Still No Reason For Optimism
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
